The generic exclusivity period for the hepatitis B treatment Vemlidy expires on the 15th of this month. Five additional companies that have received approval for generic drugs for this ingredient are expected to enter the market. The pharmaceutical industry is paying attention to whether the original will have an impact on the market share, which accounts for 99%.

According to the Ministry of Food and Drug Safety on the 6th, the generic exclusivity period for Daewoong's Vemliver, Dong-A ST's Vemlia, and Chong Kun Dang's Tenofobell-A expires on the 15th of this month. Three companies avoided the Vemlidy salt patent in March last year. They succeeded in evading the patent by using a salt different from t